Open Access

Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease

  • Authors:
    • Dewei Wang
    • Ping Wang
    • Xianli Bian
    • Shunliang Xu
    • Qingbo Zhou
    • Yuan Zhang
    • Mao Ding
    • Min Han
    • Ling Huang
    • Jianzhong Bi
    • Yuxiu Jia
    • Zhaohong Xie
  • View Affiliations

  • Published online on: May 5, 2020     https://doi.org/10.3892/mmr.2020.11118
  • Pages: 227-238
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non-coding RNA (lncRNA) and exosomes are involved in the pathological process of Alzheimer's disease (AD), the pathological changes of which are usually first observed in the entorhinal cortex and hippocampus. The aim of the present study was to determine whether the measurement of plasma exosomal lncRNA combined with image data of the entorhinal cortex and hippocampus could be used as a biomarker of AD. A total of 72 patients with AD and 62 controls were recruited, and the expression levels of several lncRNAs were assessed. Of the recruited participants, 22 patients and 26 controls received brain 3D‑BRAVO sequence magnetic resonance imaging (MRI) scans, which were analyzed using an automated analysis tool. The plasma exosomal β‑site amyloid precursor protein cleaving enzyme‑1‑antisense transcript (BACE1‑AS) levels in patients with AD were significantly higher compared with the controls (P<0.005). Receiver operating characteristic curve analysis revealed that the area under the curve (AUC) was 0.761 for BACE1‑AS, the sensitivity was 87.5%, and the specificity was 61.3%. Analysis of MRI images indicated that the right entorhinal cortex volume (P=0.015) and thickness (P=0.022) in patients with AD were significantly smaller. The AUC was 0.688 for the right entorhinal cortex volume, with a sensitivity of 59.1%, and the specificity was 84.6%. The AUC was 0.689 for right entorhinal cortex thickness, with a sensitivity of 80.8%, and the specificity was 59.1%. A series‑parallel test which integrated the BACE1‑AS with the right entorhinal cortex volume and thickness, raised the specificity and sensitivity to 96.15 and 90.91%, respectively. A logistic regression model demonstrated that combination of the 3 indices provided improved sensitivity and specificity simultaneously, particularly when adjusting for age and sex (AUC, 0.819; sensitivity, 81%; specificity, 73.1%). The results of the present study demonstrated that detection of plasma exosomal BACE1‑AS levels combined with the volume and thickness of the right entorhinal cortex may be used as a novel biomarker of AD.
View Figures
View References

Related Articles

Journal Cover

July 2020
Volume 22 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, D., Wang, P., Bian, X., Xu, S., Zhou, Q., Zhang, Y. ... Xie, Z. (2020). Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease. Molecular Medicine Reports, 22, 227-238. https://doi.org/10.3892/mmr.2020.11118
MLA
Wang, D., Wang, P., Bian, X., Xu, S., Zhou, Q., Zhang, Y., Ding, M., Han, M., Huang, L., Bi, J., Jia, Y., Xie, Z."Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease". Molecular Medicine Reports 22.1 (2020): 227-238.
Chicago
Wang, D., Wang, P., Bian, X., Xu, S., Zhou, Q., Zhang, Y., Ding, M., Han, M., Huang, L., Bi, J., Jia, Y., Xie, Z."Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease". Molecular Medicine Reports 22, no. 1 (2020): 227-238. https://doi.org/10.3892/mmr.2020.11118